CDC director denies report of ‘banned words’ in budget documents

The Centers for Disease Control and Prevention (CDC) disputed a report in the Washington Post that seven words or phrases, including “fetus,” “transgender” and “science-based,” had been banned from the agency’s budget documents, while other officials said the motivation was to avoid words that could limit chances of obtaining funding from Congress.

The initial story published on Dec. 15 said CDC policy analysts were told not to use the following terms: “vulnerable,” “entitlement,” “diversity,” “transgender,” “fetus,” “evidence-based” and “science-based.” One unnamed CDC analyst said the reaction to the reported ban was “incredulous.”

“It was very much, ‘Are you serious? Are you kidding?’” the analyst said.

Two days later, CDC director Brenda Fitzgerald, MD, disputed the story, saying the agency “remains committed to our public health mission as a science- and evidence-based institution.”

“I want to assure you there are no banned words at CDC,” Fitzgerald tweeted. “We will continue to talk about all our important public health programs.”

HHS spokesman Matt Lloyd was more forceful in his denial of the report, saying in a statement was “a complete mischaracterization of discussions regarding the budget formulation process.”

The New York Times spoke to several former federal officials, who asked not to be named, who suggested this wasn’t really a ban on certain words, but rather suggestions on certain language to avoid in order to win approval for projects from the political appointments at HHS and CDC.

“It’s absurd and Orwellian, it’s stupid and Orwellian, but they are not saying to not use the words in reports or articles or scientific publications or anything else the CDC does,” a former official said. “They’re saying not to use it in your request for money because it will hurt you. It’s not about censoring what CDC can say to the American public. It’s about a budget strategy to get funded.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.